arrow_back Back to App

Protecting Drug Supply Chain: Origin Registry and Ban on China-Made Purchases

This act aims to enhance the security of drug supplies in the U.S. by creating a registry of drug ingredient origins and gradually phasing out federal agency purchases of drugs and their ingredients manufactured in China. Citizens can expect greater transparency regarding drug origins and a potential increase in domestic pharmaceutical production, which might affect the availability and pricing of certain products.
Key points
A public registry will be established for the country of origin of all drugs and their active ingredients marketed in the U.S., with a specific focus on those produced in China.
Federal agencies (Health, Veterans Affairs, Defense) will gradually restrict, and by 2024, completely ban the purchase of drugs whose active ingredients originate from China.
Tax incentives (100% expensing) will be introduced for companies investing in building or expanding pharmaceutical and medical device manufacturing facilities in the U.S., encouraging domestic production.
Drug labeling will be required to specify the country of origin for each active ingredient, increasing transparency for consumers.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_7121
Sponsor: Rep. Gallagher, Mike [R-WI-8]
Process start date: 2022-03-17
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Protecting our Pharmaceutical Supply Chain from China Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_7121.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-03-17.

What are the main provisions?

Key points include:

  • A public registry will be established for the country of origin of all drugs and their active ingredients marketed in the U.S., with a specific focus on those produced in China.
  • Federal agencies (Health, Veterans Affairs, Defense) will gradually restrict, and by 2024, completely ban the purchase of drugs whose active ingredients originate from China.
  • Tax incentives (100% expensing) will be introduced for companies investing in building or expanding pharmaceutical and medical device manufacturing facilities in the U.S., encouraging domestic production.
  • Drug labeling will be required to specify the country of origin for each active ingredient, increasing transparency for consumers.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Gallagher, Mike [R-WI-8].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

CATEGORIES

Health Economy